Trial of Taselisib in Overgrowth

NCT ID: NCT03290092

Last Updated: 2026-02-04

Basic Information

• Recruitment Status: TERMINATED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 19 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-07-31
• Study Completion Date: 2019-11-04

Brief Summary

Segmental overgrowth disorders are rare conditions characterised by abnormal growth which is usually asymmetric and confined to discrete parts of the body. We and others have identified mosaic activating mutations in the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K; encoded by the PIK3CA gene) in a subset of overgrowth disorders. The PI3K-AKT-mTOR is a critical signalling pathway, which regulates cellular growth, proliferation and survival. Activating mutations in PIK3CA lead to increased activation of the PI3K-AKT-mTORC1 axis, which in turn promotes excessive growth in affected tissue.

The PIK3CA-related overgrowth spectrum is wide, and depends upon the timing of the founder mutation in embryogenesis, and potentially upon the exact mutation. Clinical presentation ranges from isolated enlargement of a digit, to extensive overgrowth of limbs, abdomen and in some cases the brain, and may be accompanied by vascular or lymphatic malformations. Associated morbidity can be profound, with functional impairment, debilitating haemorrhages and thromboses, coupled with neurological sequelae and, in some cases, death. At present, serial debulking surgery is the only available therapeutic option.

The identification of gain-of-function mutations in PI3K has raised the possibility of treatment with drugs that inhibit PIK3CA (the p110 alpha catalytic subunit of PI3K). Taselisib is a selective inhibitor of class I PI3Ks and has direct inhibitory activity of the p110α isoform with a Kiapp value of 0.29 nmol/l.

Conditions

PIK3CA-Related Overgrowth

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Treatment

Group Type: EXPERIMENTAL

Taselisib (GDC0032)

Intervention Type: DRUG

The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.

Taselisib (GDC0032)

Intervention Type: DRUG

The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.

Interventions

Taselisib (GDC0032)

The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.

Intervention Type: DRUG

Taselisib (GDC0032)

The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Have given, or their legal representative has given, written informed consent to participate
• Aged 16 years to 65 years inclusive
• Male or female
• Post-zygotic PIK3CA mutation
• Clinically stable in the opinion of the investigator
• Participant Pregnancy and contraception:

o Female participants of child bearing potential must use an effective method of contraception during treatment and for at least 3 months after the final dose of taselisib. Acceptable methods are:

• True abstinence (this must be the participant's usual and preferred lifestyle, not just for the duration of the trial)
• Oral contraceptive (either combined or progestogen alone)
• Contraceptive implant, injections or patches
• Vaginal ring
• Intrauterine device (IUD, coil or intrauterine system)
• Condom and cap
• Diaphragm plus spermicide

• A female participant of child bearing potential is defined as a sexually mature woman not surgically sterilized or not post-menopausal for at least 12 consecutive months if aged 55 years or older.
• Men must use one of the following, reliable forms to contraception for the entire duration of treatment and for 3 months after the final dose of taselisib:
• Condom plus spermicide even if female partner is using another method of contraception (Men should also use a condom to protect male partners, or female partners who are pregnant or breast feeding, from exposure to the Trial medicine in semen).
• True abstinence (this must be the participant's usual and preferred lifestyle, not just for the duration of the Trial)

Exclusion Criteria

• Pregnant or breastfeeding
• HIV infection
• Hypersensitivity to taselisib or any of its excipients
• Any current medical disorder or medication likely to impair ability to follow the trial protocol safely and effectively
• Are concurrently taking an mTOR inhibitor or any other small molecule inhibitor of the PI3K-AKT signalling pathway
• Unable or unwilling to give informed consent
• Sirolimus or taselisib treatment in 12 weeks prior to screening
• Treatment with a strong inducer or inhibitor of CYP3A4 without the possibility to stop this medication within the week prior to the screening. This includes:
• Macrolide Antibiotics: clarithromycin, telithromycin, erythromycin, troleandomycin
• Gastrointestinal prokinetic agents: metoclopramide.
• Antifungals: itraconazole, ketoconazole, fluconazole, voriconazole, clotrimazole
• Calcium channel blockers: verapamil, diltiazem, nicardipine
• Grapefruit containing foods/drinks
• Anticonvulsants: carbamazepine, phenobarbital, phenytoin
• Antibiotics: rifampicin, rifabutin, rifapentine
• Herbal preparations: St. John's wort (Hypericum perforatum). Other drugs: bromocriptine, cimetidine, danazol, cyclosporine, lansoprazole, calcium containing antacids.
• Inability to attend trial visits
• If less than 3 months post- major surgery at screening
• Any past medical history of inflammatory bowel disease or chronic diarrhoea of unknown aetiology
• History of type 1 or type 2 diabetes mellitus requiring insulin, GLP-1 analogues or oral hypoglycaemic agents.
• History of inflammatory bowel disease, ischemic colitis, or colitis of unknown origin.
• Fasting blood glucose > 6.9 mmol/l
• HbA1C > 6%
• Long QT, congenital or acquired
• Active pneumonitis
• Patients who require daily supplemental oxygen
• Inadequate renal function defined as creatinine clearance or radioisotope GFR < 60ml/min/1.73 m²
• Inadequate liver function defined as:
• Total bilirubin > 2.0 x ULN or conjugated bilirubin > 2.0 x ULN for age, and
• SGPT (ALT) or SGOT (AST) ≥ 1.5 x ULN for age, and
• Serum albumin < 30 g/L
• Inadequate fasting LDL cholesterol > 4.2 mmol/l
• Deprived of freedom by an administrative or court order, or benefiting from a system of legal protection (tutorship, curatorship or safeguard of justice).
• Not covered by health insurance

• Minimum Eligible Age: 16 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Centre Hospitalier Universitaire Dijon

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

CHU d'Angers

Angers, , France

CHU de Bordeaux - GH Pellegrin

Bordeaux, , France

Chu Dijon Bourgogne

Dijon, , France

Hôpital Raymond Poincaré (AP-HP)

Garches, , France

Hôpital Jeanne de Flandre

Lille, , France

HCL - Hôpital femme-mère-enfant

Lyon, , France

Hôpital Arnaud de Villeneuve

Montpellier, , France

Hôpital Saint Eloi

Montpellier, , France

CHU Hôtel Dieu

Nantes, , France

CHU de Nice - Hôpital l'Archet 2

Nice, , France

Hôpital Necker-Enfants malades

Paris, , France

Hôpital Sud

Rennes, , France

CHU La Réunion - Site GHSR

Saint-Pierre, , France

CHU de Saint-Etienne Hôpital Nord

Saint-Priest-en-Jarez, , France

Hôpital Larrey

Toulouse, , France

Hôpital Trousseau

Tours, , France

CHU de Nancy - Hôpital de Brabois

Vandœuvre-lès-Nancy, , France

CHU de Nancy

Vandœuvre-lès-Nancy, , France

Countries

France

References

Luu M, Vabres P, Devilliers H, Loffroy R, Phan A, Martin L, Morice-Picard F, Petit F, Willems M, Bessis D, Jacquemont ML, Maruani A, Chiaverini C, Mirault T, Clayton-Smith J, Carpentier M, Fleck C, Maurer A, Yousfi M, Parker VER, Semple RK, Bardou M, Faivre L. Safety and efficacy of low-dose PI3K inhibitor taselisib in adult patients with CLOVES and Klippel-Trenaunay syndrome (KTS): the TOTEM trial, a phase 1/2 multicenter, open-label, single-arm study. Genet Med. 2021 Dec;23(12):2433-2442. doi: 10.1038/s41436-021-01290-y. Epub 2021 Aug 12.

Reference Type: RESULT

PMID: 34385668 (View on PubMed)

Other Identifiers

OLIVIER-FAIVRE ROCHE 2016

Identifier Type: -

Identifier Source: org_study_id